small molecule

ZOMETA

ZOLEDRONIC ACID

Loss of exclusivity—loss of exclusivity

CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand name	ZOMETA
Active ingredient	ZOLEDRONIC ACID
Strength	EQ 4MG BASE/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	INJECTABLE
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	March 2003
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.